Facilities

....................................................................................

SinoMab has established a full-scale antibody re-engineering laboratory at the headquarter in Hong Kong.   All upstream laboratory works involving product development and other proprietary technologies are performed in Hong Kong. In September 2004, SinoMab debuted a cGMP pilot manufacturing plant of size over 1,100 sq. meters in Shenzhen. The plant was designed and equipped to produce multiple monoclonal antibody candidates for Phase I and Phase II clinical production at typical pharmaceutical margins. In anticipation of marketing production upon Biologic License Application (BLA) approval, an Antibody Development Center comprising a State-of-the-Art R&D facility and a cGMP manufacturing plant of size over 25,000 sq. meters has been established in Haikou, Hainan Province, China.

Photos of our facilities